Physicochemical Properties
| Molecular Formula | C22H26FN5O |
| Molecular Weight | 395.47 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | 5-HT1A Receptor 160 nM (EC50) 5-HT2A Receptor 96.4 nM (Kb) D2 Receptor 45.7 nM (Kb) |
| ln Vitro | Antipsychotic agent-2 (Compound 11) exhibits antagonism to D2 (Kb=45.7 nM) by inhibiting the generation of cAMP triggered by Forskolin in CHO-K1 cells that stably express human D2 receptors. It also antagonizes 10-6 M dopamine [1]. Antipsychotic agent-2 acts as a 5-HT2A antagonist against the inositol phosphate production stimulated by 10-6 M 5-HT in CHO-K1 cells expressing 5-HT2A receptors (Kb=96.4 nM), while it inhibits the Forskolin-stimulated cAMP production in HEK293 cells stably expressing the 5-HT1A receptor in a concentration-dependent manner, demonstrating agonist activity against 5-HT1A (EC50=160 nM) [1]. The CYP3A4 inducer antipsychotic agent-2 (0.1–10 μM) is comparatively ineffective [1]. Antipsychotic agent-2 (0.3-30 μM; 72 h) has notable cytotoxicity against SH-SY5Y, but only at 30 μM does it show good safety [1]. |
| ln Vivo | Compound 11 (antipsychotic agent-2; 20-80 mg/kg; intraperitoneally; once) modifies spontaneous locomotor activity in mice in a way that is statistically significant [1]. Mice with amphetamine-induced ADHD respond better to antipsychotic agent-2 (40 mg/kg; ip; once) [1] |
| Animal Protocol |
Animal/Disease Models: Naive Swiss male mice, amphetamine-induced hyperactivity[1] Doses: 40 mg/kg Route of Administration: IP, once Experimental Results: diminished amphetamine-induced hyperactivity. |
| References | [1]. Stępnicki P, et al. Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents - Design, synthesis, structural studies and pharmacological profiling. Eur J Med Chem. 2023 Apr 5;252:115285. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5286 mL | 12.6432 mL | 25.2864 mL | |
| 5 mM | 0.5057 mL | 2.5286 mL | 5.0573 mL | |
| 10 mM | 0.2529 mL | 1.2643 mL | 2.5286 mL |